ContraVir Pharmaceuticals Selected to Present Poster on TXL™ at the Upcoming AASLD Meeting® 2017
August 08 2017 - 6:00AM
ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical
company focused on the development and commercialization of
targeted antiviral therapies, announced today an abstract for TXL™
has been selected by the Scientific Program Committee of the
American Association for the Study of Liver Diseases (AASLD) for a
poster presentation on October 21, 2017.
WHAT: Tenofovir exalidex (TXL™) is a highly
potent prodrug of the antiviral tenofovir. Tenofovir is the
active component of both Vemlidy (tenofovir alafenamide) and
Viread® (tenofovir disoproxil fumarate). TXL’s novel
liver-targeting prodrug structure results in decreased systemic
circulating levels of tenofovir, thereby reducing the potential for
renal and bone side effects. ContraVir has completed a Phase 2a
trial of TXL™, in which HBV-infected subjects were administered
doses up to 100 mg for 28 days and is now working to optimize the
formulation to further enhance drug delivery. To date, TXL™ has
achieved clinical proof of concept for antiviral activity and
displayed an excellent safety, tolerability, and pharmacokinetic
profile. Based on the agent’s best-in-class potential, ContraVir
believes TXL™ can become the cornerstone of a curative combination
therapy for hepatitis B.
Abstract: "Pharmacokinetics, Safety and
Antiviral Activity of Tenofovir exalidex (TXL), A Novel Prodrug of
Tenofovir, Administrated as Ascending Multiple Doses to
HBV-Infected Subjects: A 28 Day Study Final Analyses"
- Publication Number: 943
- Date and Time: October 21, 2017 from 2:00
PM to 7:30 PM
- Session: Hepatitis B: New and Approved
Treatment
- Location: Washington Convention Center, Hall
D
WHO: Tawesak Tanwandee, MD. Associate
Professor of Medicine Division of Gastroenterology Department of
Medicine, Siriraj Hospital, Mahidol University will be available
for interviews in advance via teleconference or onsite.
About ContraVir Pharmaceuticals
ContraVir is a biopharmaceutical company focused on the
development and commercialization of targeted antiviral therapies
with a specific focus on developing a potentially curative therapy
for hepatitis B virus (HBV). The Company is developing two novel
anti-HBV compounds with complementary mechanisms of action. TXL™
currently in Phase 2a, is designed to deliver high intrahepatic
concentrations of TFV, while minimizing off-target effects caused
by high levels of circulating TFV. CRV431, the other anti-HBV
compound, is a next-generation cyclophilin inhibitor with a unique
structure that increases its potency and selective index against
HBV. ContraVir is also developing Valnivudine™, an orally available
nucleoside analogue prodrug; Valnivudine™ is currently in Phase 3
for the treatment of herpes zoster. In addition to direct
antiviral activity, Phase 2 data suggest that Valnivudine™ has the
potential to reduce the incidence of debilitating
shingles-associated pain known as post-herpetic neuralgia
(PHN). For more information visit www.contravir.com.
Forward Looking Statements Certain statements
in this press release are forward-looking within the meaning of the
Private Securities Litigation Reform Act of 1995. These statements
may be identified by the use of forward-looking words such as
"anticipate," "believe," "forecast," "estimated" and "intend,"
among others. These forward-looking statements are based on
ContraVir's current expectations and actual results could differ
materially. There are a number of factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a
going concern; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. ContraVir does
not undertake an obligation to update or revise any forward-looking
statement. Investors should read the risk factors set forth in
ContraVir's Form 10-K for the year ended June 30, 2016 and other
periodic reports filed with the Securities and Exchange
Commission.
For further information, please contact:
Sharen Pyatetskaya
Director of Investor Relations
sp@contravir.com; (732) 902-4028
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Contravir Pharmaceuticals Inc (NASDAQ:CTRV)
Historical Stock Chart
From Apr 2023 to Apr 2024